Consequently, the PD-1/PD-L1 blockade therapy, which directly restores suppressed host antitumor immune responses, has significantly improved the clinical prognosis of many patients with advanced and resectable NSCLC (38–40). This evidence concerns the gene CD274 and non-small cell lung carcinoma.